Related Content
Download content relating to this event and topic.
No items found.
Biologics World South East Asia 2026
Launch
SEA’s Only End-to-End Therapeutic Biologics Platform
Biologics World Southeast Asia 2026 brings together senior decision-makers across biopharma, biotech, and manufacturing to drive innovation, scale-up, and commercialisation of therapeutic biologics across the ASEAN region
Jakarta, Indonesia
14
October
-
15
October
2026
00
Days
00
Hours
00
Mins
00
Secs
100
+
Attendees
Maximum Attendees
50
+
Companies
30
+
Speakers
16
+
Networking Hours
8
+
Case Studies
Interactive Sessions
About the Event
Biologics World Southeast Asia is a premier regional platform dedicated to advancing the development, manufacturing, and commercialisation of therapeutic biologics across ASEAN. The conference convenes senior leaders from biopharma, biotech, CDMOs, academia, regulators, investors, and technology providers to address the strategic opportunities shaping Southeast Asia’s biologics landscape.
As demand for monoclonal antibodies, biosimilars, and next-generation biologics continues to rise across the region, Southeast Asia is emerging as a critical hub for clinical development, manufacturing expansion, and healthcare innovation. Governments across Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the wider ASEAN region are accelerating investments into life sciences infrastructure, regulatory strengthening, and local production capabilities to enhance healthcare resilience and reduce reliance on imports.
The conference explores the full therapeutic biologics value chain — from R&D and translational science to bioprocessing, manufacturing scale-up, CDMO partnerships, and market access. Through strategic discussions and real-world case studies, the programme highlights regional capabilities, investment priorities, and collaboration opportunities driving the growth of biologics adoption in Southeast Asia.
Biologics World Southeast Asia is co-located with the Vaccine World Southeast Asia Congress, creating a unified platform that brings together stakeholders across the broader biopharmaceutical ecosystem. While the Vaccine Congress focuses on infectious diseases, immunisation strategies, and vaccine innovation, Biologics World Southeast Asia maintains a dedicated emphasis on therapeutic biologics, including monoclonal antibodies, biosimilars, antibody-drug conjugates (ADCs), and protein therapeutics.
This co-located format enables cross-industry exchange while preserving distinct scientific and commercial discussions, fostering stronger partnerships across research, manufacturing, and healthcare delivery.
By convening global and regional decision-makers under one platform, Biologics World Southeast Asia aims to support Southeast Asia’s transformation into a competitive biologics hub - strengthening manufacturing capabilities, improving patient access to advanced therapies, and positioning ASEAN as a key contributor within the global biologics value chain.
Agenda at a Glance
View the Key Themes for
Biologics World South East Asia 2026
Day 1 | October 14 2026
- Plenary Session: Building Southeast Asia’s Biologics & Vaccine Ecosystem
- Biopharma Showcase Therapeutic Biologics Market Growth in Southeast Asia
- R&D & Translational Science for Biologics
- Clinical & Market Access for Therapeutic Biologics
Awards Ceremony : AVEA2026
Day 2 | October 15 2026
- Bioprocessing & Manufacturing Innovation in South East Asia
- CDMO & Tech Transfer Partnerships in South East Asia
- Future Modalities in SEA: ADCs & Protein Therapeutics
- Leadership Panel Discussion: Can Southeast Asia Become a Global Biomanufacturing Powerhouse?
Ready to attend?
Register today to secure your ticket.
Speakers
Esteemed Voices From the Industry
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.
Shanti Marlina Sibuea
The Indonesian FDA (Badan POM)
Acting Director, Directorate of Control of Production of Drug, Narcotic, Psychotropic and Precursor
Indonesia
Shanti Marlina Sibuea is the Acting Director of the Directorate of Production of Drug, Narcotic, Psychotropic and Precursor Control at the Indonesian FDA (Badan POM). With over 15 years of experience as a GMP inspector, she has led and participated in numerous international inspections across China, India, South Korea, Japan, and Puerto Rico. Her expertise spans regulatory systems, quality management, and oversight of biological products and advanced therapies. She serves as a PIC/S assessor and actively contributes to global regulatory convergence, including international regulatory assessments and expert circles on ATMPs. She holds a PhD from Monash University, focusing on stem cell and regenerative medicine, and supports national and regional capacity building in regulatory science.
Advisory Board Commitee
Chairman
Shanti Marlina Sibuea
Acting Director, Directorate of Control of Production of Drug, Narcotic, Psychotropic and Precursor
The Indonesian FDA (Badan POM)
Indonesia
Advisory Board Commitee
Chairman
Rakhmat Budi Yuwono
Quality Director
Etana Technologies
Indonesia
Badarulhisam Abdul Rahman, PhD
Pharmaniaga Berhad
Chief Scientific Officer
Malaysia
Dr. Badarulhisam is currently the Chief Scientific Officer at Pharmaniaga Berhad. He is responsible to spearhead product development and regulatory strategies for the company, inclusive of product ideation, development, trial, registration and product life cycle management. Among others, he is currently leading the team for various biopharma and vaccine development program, either through in house development or through technology transfer from several international strategic partners.
Dr Badarulhisam qualified as a Biochemical Engineer. He received his PhD from the Johns Hopkins University, USA and MSc and Advanced Diploma from the University College of London, UK. His area of expertise is in the fields of Biochemical Engineering and Biotechnology. Dr. Badarulhisam developed his early career as a lecturer at the Department of Bioprocess Engineering, University Technology of Malaysia and he is still active academically. He has served as a Professor (adjunct) at Chemical Engineering Department, University Putra Malaysia and he is also a member for the Board of Academic Advisory, School of Pharmacy, Universiti Kebangsaan Malaysia and a few other universities. He has served as an industrial advisor to several Bioprocess Engineering Programs in major universities in Malaysia and co supervises Masters and PhD students in various aspects of Biopharmaceutical Plant Design, Biologics Drug Development and Process Optimizations.
Advisory Board Commitee
Chairman
Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer
Pharmaniaga Berhad
Malaysia
Dr. Mohd Azlan bin Zaharudin
Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)
Director
Malaysia
Dr. Mohd Azlan Bin Zaharudin is the Director of the Malaysian Vaccine Project Office (MVPO) under the Ministry of Science, Technology, and Innovation (MOSTI). In this role, he oversees the coordination and implementation of strategies related to Malaysia's National Vaccine Development Roadmap (NVDR). His responsibilities include leading efforts in vaccine ecosystem development and facilitating collaborations to advance vaccine innovation in Malaysia.
Prior to his role at MVPO, Dr. Mohd Azlan was part of the Strategic Technology and S&T Application Division of MOSTI, where he focused on the biotechnology sector. His work in this division provided him with valuable insights and experience that he now applies to his current position.
Advisory Board Commitee
Chairman
Dr. Mohd Azlan bin Zaharudin
Director
Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)
Malaysia
Want to Speak at This Event?
Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.
Apply to SpeakRegistration
Select the relevant ticket for your organisation.
*Delegate tickets must be purchased under the correct classification.
Biopharma tickets are strictly reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own, or commercialise therapeutic drug products, including organisations with an internal drug pipeline spanning discovery, development, clinical, or commercial stages. This category applies to companies whose primary business is the development or manufacture of drug products, not the provision of enabling technologies, equipment, platforms, or services.
Service, Solution, and Technology Provider tickets apply to all organisations offering services, platforms, technologies, equipment, consultancy, manufacturing services, or commercial solutions to the pharma and biopharma industry. This includes, but is not limited to, CROs, CDMOs, technology and equipment vendors, consultants, suppliers, and solution providers, regardless of scientific or technical focus.
Important Notice
All registrations are reviewed to ensure correct classification. Purchasing an incorrect ticket does not guarantee entry to the event. IMAPAC retains full discretion to deny access, reclassify registrations, and issue an invoice for the price difference required for correct attendance. Incorrect ticket purchases made under an inappropriate classification are not eligible for refunds under any circumstances, including where the registrant chooses not to upgrade or attend.
BioPharma & Academic Based in Asia
Starts from SGD 1,495
Early Bird Rate : SGD 1,495
(Valid until 15th May 2026)
Registration Open Rate : SGD 1,695
(Valid until 17th July 2026)
Standard Rate : SGD 1,895
(Valid until 18th September 2026)
Final Call Rate : SGD 2,095
(Valid until 141th October 2026)
Applicable to company profiles (headquartered within the APAC region):
- BioPharma
- Academic Institutions
- Research Organisations
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
BioPharma & Academic Based Outside of Asia
Starts from SGD 1,995
Early Bird Rate : SGD 1,995
(Valid until 15th May 2026)
Registration Open Rate : SGD 2,195
(Valid until 17th July 2026)
Standard Rate : SGD 2,395
(Valid until 18th September 2026)
Final Call Rate : SGD 2,595
(Valid until 141th October 2026)
Applicable to company profiles (headquartered outside of the APAC region):
- BioPharma
- Academic Institutions
- Research Organisations
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Big Pharma & Solution Providers
Starts from SGD 2,995
Early Bird Rate : SGD 2,995
(Valid until 15th May 2026)
Registration Open Rate : SGD 3,195
(Valid until 17th July 2026)
Standard Rate : SGD 3,395
(Valid until 18th September 2026)
Final Call Rate : SGD 3,595
(Valid until 14th October 2026)
Applicable to company profiles:
- Big Pharma
- Technology, Service, and Solution Providers
- CDMO/ CMO
Job Profiles: Business Development, Marketing, and Sales
Registration
Register Your Interest
Be the first in line!
Register your interest to get access to tickets as soon as they go live.
Want to Sponsor This Event?
Contact the IMAPAC to learn about our sponsorship process, rates and more.
Pre Conference Workshops & Other Sessions
Visit the event page to view more content.
No items found.
Co-Located Events
Visit the event page to view more content.
Awards Cerermony
Visit the awards page to view more content.
Frequently Asked Questions
How can I stay updated on event details and announcements?
To stay informed about event updates, including date, venue, and agenda, please subscribe to our our official social media channels for real-time updates and announcements.
What can I expect to learn and explore during the event?
The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.
What safety measures will be in place to ensure the safety of attendees?
We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.
Can I submit a presentation to be a speaker at this event?
We welcome presentation submissions. If you’re interested in speaking at the event, please visit this page on our website for submission guidelines and deadlines.
What type of professionals benefit most from attending?
Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.
What advantages does this conference offer participants?
Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals
Are there networking opportunities or special events planned?
Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.
Are there sponsorship opportunities for this event?
Yes, we offer sponsorship and exhibition opportunities for businesses and organisations.
How can I register for the event?
To register for the event, you'll find multiple "register" buttons on this page to get started. You’ll find detailed instructions and options for registration, including pricing and deadlines.
Be a Part of This Event!
Don't miss out on unique networking, speaking and sponsorship opportunities.